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Abstract: Unmet clinical diagnostic needs exist for many complex diseases, which it is hoped will
be solved by the discovery of metabolomics biomarkers. However, as yet, no diagnostic tests based
on metabolomics have yet been introduced to the clinic. This review is presented as a research
perspective on how data analysis methods in metabolomics biomarker discovery may contribute to
the failure of biomarker studies and suggests how such failures might be mitigated. The study design
and data pretreatment steps are reviewed briefly in this context, and the actual data analysis step is
examined more closely.
Keywords: complex disease; heterogeneous disease; biomarker discovery; data analysis;
metabolomics; reproducibility; modeling; precision medicine
1. Introduction
Unmet clinical diagnostic needs exist for many complex diseases, which it is hoped will be solved
by the discovery of metabolomics biomarkers. However, the molecular biomarker discovery effort
and the field of precision medicine are currently experiencing skepticism and a loss of credibility
due to high failure rates of the majority of proposed biomarkers in subsequent validation studies [1].
The United States Food and Drug Administration (FDA) currently only approves one to three new
biomarkers a year, despite abundant literature on proposed novel molecular biomarkers [2]. There
have been no metabolomics tests with FDA clearance since the emergence of modern metabolomics [3].
Putative biomarkers are failing at the initial verification and validation stages, and the “science of
biomarker failures” has been described as ubiquitous, with less than 1% of published biomarkers
entering clinical practice [4].
Clearly, there are problems in the biomarker discovery pipeline that are not conveying appropriate
biomarker candidates for clinical application. Biomarker failure begins in discovery [5]. There are
numerous opportunities for fatal flaws to accumulate from the early biomarker discovery phase (the
preclinical exploratory phase) leading to the failure of a biomarker discovery project, including, but not
limited to, poorly designed, underpowered studies that fail to take account of disease heterogeneity; false
discoveries from biological variability or technically induced variability; inappropriate employment of
data analysis methods and subsequent incorrect interpretation of findings, leading to over optimistic
and misleading preliminary results; a lack of expert knowledge incorporated into the discovery phase;
and promotion of discriminating, but not necessarily clinically actionable, candidate biomarkers [4].
For this review, the starting point of data analysis is deemed to be the metabolomics data
matrix that exists after preprocessing (alignment, peak identification, batch correction, etc.) has been
carried out. Such preprocessing methods are often platform dependent, and there are many open
source software options for the data preprocessing step. A detailed list of open source software
for metabolomics preprocessing (and indeed other aspects of metabolomics data analysis) has been
compiled by Spicer et al. [6]. Obviously, there are challenges at the preprocessing stage of the pipeline,
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which will also affect subsequent analysis and successful biomarker discovery. For issues and challenges
related to data preprocessing, the reader is directed to several comprehensive reviews in that area [7–9].
However, an examination of all the issues related to biomarker failures in the discovery phase is
beyond the scope of this review, which is presented as a perspective on how data analysis methods
in metabolomics may contribute to the failure of biomarker studies. The study design and data
pretreatment steps are reviewed briefly in this context, and the actual data analysis step is examined
more closely.
2. Definition of a Complex Disease
First, however, we will define a complex disease. Most common complex diseases are categorised
according to superficial, clinically observable features. At a molecular level these complex diseases are
suspected to be polygenic, arising from the interplay of many genetic factors (and interactions with
the environment). Some complex diseases could be heterogeneous, in which many different subtypes
exist, themselves comprised of polygenic disorders, but not necessarily so, as they could comprise a
homogenous group of diseases arising from the same polygenic architecture or gene set. Conversely,
heterogeneous disorders could be complex (arising from many different polygenic variants), but also
not necessarily so, as they could actually consist of a grouping, under an umbrella term, of a collection
of phenotypically similar disorders, each arising from a single rare genetic variant.
In the early stages of the Genome Wide Association Studies (GWAS) era, complex diseases were
suspected to arise from many common variants [10]. However GWAS did not uncover the expected
common variants that would explain polygenic inheritance but instead lead to the identification of
many rare individually causal variants, indicating a high degree of genetic heterogeneity underlying
common complex conditions [11,12]. Currently, the view of complex diseases is that so-called common
disorders actually encompass many distinct genetic disorders. GWAS are not expected to reveal
predictive biomarkers of disease, as most complex disease susceptibility variants have not shown a
clear association with prognosis [13]. Metabolomics is the omics domain expected to overcome the
limitations of GWAS as a diagnostic/predictive biomarker tool, as it represents the endpoint of the
omics cascade and is the closest domain to the phenotype [13,14]. Also, particularly usefully for the
identification of diagnostic biomarkers for complex diseases, depending on sample timing, samples in
a metabolomics dataset may represent the convergence, in a common metabolic pathway, of many
diverse etiological pathways (that arise from different genetic origins). This would cause the samples
to exhibit the same phenotypic traits and have similar metabolomic profiles. However, no diagnostic
tests based on metabolomics have yet been introduced to the clinic. Among the reasons for this is the
failure of many preliminary findings from the exploratory phase to replicate in subsequent validation
studies [15]. This failure of subsequent reproducibility in validation tests is part of the phenomenon of
the reproducibility crisis.
The terms complex, multifactorial, and polygenic and even heterogeneous are, confusingly, often
used interchangeably in the literature when describing disease [16,17]. This is because the underlying
genetic architecture of these diseases is usually unknown. It is likely that most diseases that are known
clinically as complex diseases (and their resultant datasets) are both complex and heterogeneous, i.e., a
collection of phenotypically similar disorders each arising from varying polygenic architecture and
possibly single rare gene variants. For the remainder or this paper, complex and/or heterogeneous
disorders are referred to as CHD.
It would seem inevitable that a clear understanding and delineation of the nature of the molecular
complexity of the disease (and the dataset) under study is essential to designing an appropriate study
and data analysis plan. However, if a clear understanding of the molecular architecture is unknown
(as is usually the case), an appreciation of this serious limitation and the potential hidden substructure
in the data should be factored into the study design and the data analysis.
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3. Study Design and the Biomarker Discovery Pipeline: Considerations for Complex Disease
Experimental design for a biomarker study describes the definition of the populations of interest,
the selection of individuals to take part in the study, and the arrangement of the experimental material
in space and time. Study design, therefore, is a subsection of experimental design that concerns itself
with the selection of the individuals for the relevant phase of the biomarker discovery project. Here,
we will briefly discuss issues related to study design for the preclinical exploratory phase of a CHD
biomarker discovery project.
The preclinical exploratory phase has two goals: To identify leads for potentially useful biomarkers
and to prioritise identified leads [18]. Study design decisions in the preclinical exploratory phase are
dominated by bias, measurement, and inference concerns. However, the final study design is often a
compromise between the idealised design and a number of logistical and ethical barriers surrounding
the feasibility of recruitment and biological specimen collection [19]. Biases common in the discovery
phase are selection bias, ascertainment of endpoint bias, inappropriate selection of controls, technically
induced bias at sample acquisition and assaying stages, and bias introduced by statistical analysis. [20].
Less rigor is often employed in the discovery phase compared with the validation phase. For example,
hospital based convenient samples are often used at the exploratory stage of the biomarker project, but
these samples are often inherently biased [21]. Poor study design in the discovery phase without doubt
contributes to biomarker failure, and discovery phase study design should follow rigorous principles
to avoid bias [18,21,22].
Nested case control (NCC), a variant of the classic case control design where cases and controls
are sampled from a well-defined cohort, is the recommended study design in biomarker discovery
projects [23–25] as it is better able to handle the challenges of the effects of analytic batch, long term
storage, and freeze-thaw cycles on biomarkers. It is also logistically simple, cost effective, and can be
done with or without matching [26].
The PROspective-specimen collection, retrospective Blinded Evaluation (PROBE) study design is
a type of NCC that was introduced by Pepe and colleagues in 2008 [25] for the biomarker validation
stage, and its principles are now routinely adhered to in validation research. The PROBE design has
since been recommended as equally important for the discovery phase to minimise inherent bias [21,27].
The main principles of the PROBE guidelines are 1. Consider the clinical endpoint early in study
design. 2. Sample appropriately. 3. Collect specimens prospectively. 4. Select cases and controls
retrospectively and randomly. 5. Carry out assay in a blinded fashion. Strict adherence to the PROBE
design may not always be possible in the exploratory biomarker discovery phase, but it should be
the goal.
PROBE authors also recommend an approach to sample size calculations that is similar to previous
recommendations for sample size calculations for validation studies, except that the approach for
the discovery phase addresses its unique challenge of filtering through many candidate biomarkers.
The recommendations for the sample size calculations for the discovery phase require specifying—a
definition for biomarker performance, the proportion of useful markers that the study should identify,
and the tolerable number of useless markers among those identified. The PROBE approach allows
for the selection of a panel of markers, where each marker meets a performance criterion that may be
less than the clinical goal. The authors also draw attention to the fact that the statistical challenge of
deriving combinations of biomarkers using classification or regression techniques (as is the norm in
most metabolomics biomarker discovery studies) is “enormous” and that the enormity of the task is
“widely underappreciated” [21].
Wallstrom et al. [28] suggest using a two stage design for biomarker discovery to deal with
heterogeneity of disease. According to their pipeline, the first stage uses a portion of patients and
controls to screen the full collection of biomarker candidates to eliminate implausible markers. In
the second stage, the remaining candidates are screened using the remaining patients and controls.
The advantage of this pipeline is that in the second stage, the number of candidates is sufficiently
small that more detailed studies may be feasible. However, for heterogeneous disease, they do not
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recommend this approach for less than 100 cases and controls. An alternative approach to deal with
heterogeneity includes a “phase zero” or pre-screen [4], which is described as an “intellectual process
to identify plausible sets of markers” even before laboratory work starts.
It has been proposed that the limitations imposed by the heterogeneity of datasets in biomarker
discovery can be offset by increasing sample size [28]. Successful biomarker discovery for heterogeneous
disease requires more than double the number of cases and controls than for homogeneous disease,
and the probability of finding a true biomarker that exists in a heterogeneous dataset using 50 cases
and 50 controls is only 15% [28]. Others have countered this, however, and suggest that homogeneity
of sample groups is more important than sample size [29]. The latter point is echoed by Lemos et al.,
who state that.
From a scientific standpoint biomarker discovery should be ideally performed in relatively
homogenous populations using narrowly defined endpoints that represent the most specific phenotypes
possible. In contrast validation should be performed in diverse cohorts that better reflect the clinical
circumstances in which biomarkers might be used [30].
If homogeneous discovery populations are not possible then large sample sizes are needed [28].
Matching is frequently employed in biomarker discovery to minimise confounding. However,
matching on mediators, that are naturally connected to the outcome, will undermine the discovery
process and can lead to biased estimates of prediction performance [31], a fact which is usually
not appreciated in metabolomics literature. Matching makes controls more similar to cases on all
correlates of the matching factor [32], leading to cases and controls having similar biomarker profiles.
The ramification of this is that the performance of a valid biomarker will appear to be deflated as
true differences are obscured. Anti-matching [33] is a matching technique where cases are matched to
controls counter to known risk factors of the disease, i.e., for a disease for which age and ethnicity are
known to be associated with disease, then a control is selected for a case with a deliberately different
age category or ethnicity category. In this way, a known pattern of bias is introduced into the data,
which leads to the observed specificity of a true biomarker being higher in discovery studies.
Matching in biomarker discovery for CHD is a precarious issue as a particular exposure (variable)
associated with disease is likely to only be dysregulated in a subgroup of cases. This implies that even
for a variable/exposure of interest, a proportion of the case group that is not represented by that feature
may be more like controls than the other cases for that particular feature. Overmatching is a risk in
this situation, and biomarker discovery could be undermined. The anti-matching scheme may be
particularly suitable for CHD datasets to reveal subtle, subgroup specific biomarkers, which are at risk
of being obscured.
4. Data Pretreatment Step: Considerations for complex disease
Random and systemic bias and missing values are prevalent in (Mass Spectrometry) MS-based
data due to biological, experimental and technical reasons [34]. Typical data pre-treatment methods,
including filtering, normalization, scaling, and transformation are performed on MS datasets in an
attempt to remove biases from the data. Imputation of missing values is carried out to provide a
complete dataset for further analyses.
Data pretreatment methods, and the order in which they are applied to the data, have been found
to have a profound influence on the results of further data analysis [34,35]. Despite its importance,
however, the data pretreatment step is largely overlooked in the reporting of biomarker discovery
studies, indicating that its crucial role and influence on subsequent results are not fully appreciated [36].
At the earliest stage, before analysis starts, efforts should be made to reduce the dimensions of
the dataset wherever possible, to enable true potential biomarkers to be revealed [37] and to address
the curse of dimensionality [38]. Filtering at the outset can be performed to remove implausible
features, that is, those features unlikely to be of clinical utility, thereby also reducing the complexity of
the dataset.
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In a typical metabolomics dataset, each row represents a different sample and each column
represents a different metabolite. Sample wise normalisation describes the row-wise operations carried
out to reduce inter sample (typically inter person) variation, which is due to biological variation
and, therefore, make each row comparable to each other. Normalisation methods can be either data
driven or method driven. Data driven methods are used for untargeted (Liquid Chromatography
Mass Spectrometry) LCMS data [39] and include normalization by sum or median normalization.
Data driven methods depend upon certain assumptions, namely that a large amount of the metabolites
in a sample stay constant and that only a small portion of the features will undergo significant
experiment-related changes in expression.
Feature wise normalisation methods are column wise operations to adjust for the differences in
abundances between the individual metabolites and, therefore, make each column comparable to each
other. These include scaling, centering, and transformation. Scaling can use either a measure of the
data dispersion or a size measure as a scaling factor. Heterogeneity in the form of hidden substructure
in a disease dataset and in the form of the presence of features with dysregulation in a subset of samples
can lead to scaling factors that introduce bias into the scaled dataset. Scaling by mean or standard
deviation of controls only is one possible way of reducing bias, at least for features that are exhibiting
stable expression in controls. Inappropriate normalisation methods can significantly impair data [40].
A comprehensive description and evaluation of pretreatment methods can be found in [41], where the
authors conclude that different pretreatment methods emphasise different aspects of the data and that
pretreatment methods should be selected while bearing in mind the biological question of interest, the
properties of the dataset under investigation, and the data analysis method that will be used.
Missing values occur in LCMS data at rates of approximately 20% and affect up to 80% of
variables [35]. How these missing values are dealt with or imputed massively influences the results of
downstream analysis [35,42]. These missing values can be 1. missing completely at random (MCAR),
i.e., missing due to not being measured correctly but actually being present in the sample, or 2. missing
not at random (MNAR), i.e., abundance dependent missingness due to the abundance of the molecule
falling below the instrument detection limit or due to the molecule simply not being present in the
sample for a genuine biological reason. The typology MNAR/MCAR was coined by Rubin [43].
The majority of missing values in untargeted metabolomics data are expected to be MNAR. In the
situation that a feature has missing values because its abundance is below the limit of detection of
the instrument used, there is a possibility that it is a hormone/signaling molecule and, as such, may
hold great promise as a disease biomarker. These metabolites could potentially be identified by a more
sensitive targeted analysis, but, unfortunately, such potentially useful biomarkers will often suffer
from the masking effects of imputation at the untargeted stage, due to their high levels of missingness,
meaning that their signal is obliterated at the early stage of the discovery pipeline. As such, these
features may not end up in the list of leads to progress to the targeted stage and, therefore, may not get
an opportunity to be assessed by the more sensitive targeted methods.
The options for dealing with missing values include eliminating those features with missing
values from further analysis, ignoring those missing values during analysis, or dealing with the missing
values by imputation methods. Imputation algorithms can be broadly categorised into single value
methods, local methods, global methods, hybrid methods, and knowledge based methods [44–46].
A variety of imputation algorithms exist and have been evaluated and compared elsewhere [35,47,48]
and it is acknowledged that no single imputation method is universally superior [44,49].
For a heterogeneous disease dataset with hidden subgroups, where a disease related feature
is likely only dysregulated in a subset of cases, the issue of missing value imputation becomes
delicate. Local, global or hybrid methods are likely to be unsuitable due to the presence of an
unknown substructure in the data and also due to low sample numbers typical of most metabolomics
studies, which would prevent correlation and covariance structures from being extracted reliably [50].
The imputation method employed for such a dataset should ideally aim to ensure that masking does
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not occur of a subtle signal from a feature that could potentially act as a biomarker for a subgroup of
the disease.
The advice is to first assess if there is a need to impute [35]. Perhaps use of data analysis techniques
that do not require an imputed dataset may fare best for CHD datasets. As has been stated previously,
“any imputation method leads to bias”. An expectation of any method of imputation leading to
an approximation of a faithful representation of the original missing values may be exceptionally
unrealistic in the case of heterogeneous disease datasets. Instead, acceptance of the limitation that in
the case of CHD datasets, that imputation methods will lead to even greater bias and that resulting
imputed datasets are an approximation or artificial dataset. If, for the data analysis method being used,
a complete dataset is essential, then the bias that is being imputed into the dataset should be factored
into the data analysis. Also, post analysis and, if possible, investigation of identified differential
features, without the imputed values, is advised.
5. The Data Analysis Step: Considerations for Complex Disease
5.1. The Reproducibility Crisis in Metabolomics Biomarker Discovery
The reproducibility crisis has incited considerable discussion in recent years [51,52], since the
phrase first came to the fore when a major replication effort in psychology found that only 39% of studies
assessed were reproducible. Since then, similar replication efforts have shown that the reproducibility
crisis is a serious issue across a variety of disciplines, from cancer biology [53] to economics [54]. A 2016
survey by nature magazine showed that most scientific fields are facing a reproducibility crisis [55].
The terms reproducibility, replicibality, reliability, robustness, and generalizability all have slightly
different meanings and implications and the study in [56] can provide clarification. In this review,
results reproducibility and the related phenomenon of generalizability in metabolomics biomarker
discovery are discussed.
With regards to metabolomics biomarker discovery, the issue of results irreproducibility can
be described as the inability of results from preliminary analyses to reproduce in validation studies
despite good performance on cross-validation/permutation on the initial dataset. In the field of
metabolomics biomarker discovery, the majority of preliminary findings are not followed up by
external validation [21]. The reason for this lack of follow up could be because validation studies do
not actually take place or because validation studies are carried out and produce negative results,
which are not reported (or published). A recent systematic review examined biomarker discovery
publications where metabolomics biomarkers had been validated on an external test set (usually by
the same group, on the same publication) and showed that apparently equivalent studies, on the same
disease, obtain different biomarker lists [30].
The most often purported reasons in the literature for the reproducibility crisis in preclinical
research are lack of standards and rigor in experimental procedures, publication bias, poor data analysis
techniques, questionable research methods, selective reporting of results, studies with low statistical
power, and a “faulty incentive” culture in scientific and clinical research [52,57]. Solutions emanating
from this view of the crisis focus on open science practices, data sharing, and increased standardisation.
The above reasons for the reproducibility crisis notwithstanding, an alternative perspective on
the reproducibility crisis has begun to appear in the literature, which suggests that expectations of
reproducibility are misplaced. This view proposes that a large part of the reproducibility crisis in clinical
and preclinical research can be ascribed to a failure to account for contextual sensitivity [58], phenotypic
plasticity [59], and reaction norms [60]. This philosophy urges us to adjust our expectations [61] and,
therefore, our analysis methods. Voekl [62] shows that increasing variability, rather than reducing
it, improves reproducibility in preclinical animal studies. An [63] describes his perception of the
reproducibility crisis as a failure of typical methods of scientific investigation to account for biological
heterogeneity. Describing the denominator subspace as all possible states of a biosystem, An posits
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that typical experiments only base models on a sliver of possible outcomes and, as such, failure of
these models to be generalizable (reproducible) is inevitable.
In metabolomics biomarker discovery, as has been mentioned previously, validation efforts
of preliminary discovery findings are in the vast minority (and are almost always carried out by
the same group), and validated studies by different groups on the same disease produce different
lists of biomarkers [15]. However, metabolomics profiles from the same samples analysed across
different platforms, by different investigators, have produced comparable profiles even without
prior standardisation [64]. Together, these findings could point towards contextual sensitivity as
a possible explanation for results irreproducibility (Figure 1), as opposed to issues related to in
experimental standards.
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5.2. Multivariate Analysis and Univariate Analysis
Univariate and multivariate analysis techniques are frequently applied to metabolomics datasets
and are considered to provide complementary information. Therefore, it is advised that both analysis
methods be employed. Univariate techniques examine only one variable at a time while multivariate
techniques make use of co-variances or correlations, which reflect the extent of the relationships among
the variables. Based on the intuitive notion of gene-sets or metabolic networks, there is a general
belief that multivariate analysis is superior to univariate analysis for the discovery of biomarker
candidates [65].
However, Lai et al. show that univariate selection approaches yield generally better results
than multivariate approaches across the majority of gene expression datasets that they analysed [50].
The reason for this, they conclude, is that correlation structures, even if they are present, cannot
be extracted reliably due to low sample numbers. Another study shows that for gene extraction,
multivariate statistics do not lead to a substantial gain in power compared with univariate statistics,
even when correlations are present and high [66].
Multivariate search for biomarkers using supervised algorithms is based on the underlying
assumption of homogeneity with multiple discriminating features together representing the fingerprint
of the disease phenotype. However, in the situation where a CHD does not contain a hidden fingerprint
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for disease that is common to most or all cases, but instead exhibits perturbations in some features, in
some cases, that reflect the different etiologies of the hidden subgroups, then the biomarker(s) from
these different subsets of the disease are difficult to reveal using global methods due to their low overall
prevalence among cases in the dataset [28].
Multivariate techniques, particularly statistical learning techniques, are the de facto data analysis
methods employed for biomarker discovery in metabolomics. Instability and abstraction have been
purported as the two fundamental issues contributing to the failure of biomarkers obtained from
statistical learning approaches and are problems that are “here to stay” due to characteristics inherent
in omics datasets. Instability is due to the curse of dimensionality, and the “small n large p” problem.
Abstraction describes the data driven nature of the algorithms, which yield complex decision rules that
generally lack meaning for biologists and clinicians to “generate testable hypotheses” [38]. Partial Least
Squares Discriminant Analysis (PLSDA) is the most popular learning algorithm used in metabolomics
biomarker discovery. Its widespread availability in omics analysis software is credited (or blamed) for
the algorithm’s ubiquity in metabolomics biomarker discovery studies [67]. PLSDA, however, has
been described as an “algorithm full of dangers” and is prone to overfitting and, therefore, producing
false positive results [67–69]. PLSDA is also susceptible to misuse in the hands of non-experts [67].
For example, supervised algorithms such as PLSDA can result in biased estimations of prediction
accuracy when classifiers are used that fail to select features from scratch in each iteration of a loop
in cross-validation. This analysis flaw was found to be common in a review of microarray statistical
analyses [70]. It is reasonable to assume that such misuse of PLSDA and similar algorithms is also
an issue in metabolomics data analysis. However, poor reporting makes assessing the extent of
this problem difficult [36]. Finally, as an especially important point for the analysis of complex and
heaterogeneous datasets, Eriksson et al. note that “a necessary condition for PLSDA to work is that each
class is tight and occupies a small and separate volume in X-Space... Moreover, when some of the classes are not
homogeneous and spread significantly in X-space, the discriminant analysis does not work” [71]. Clearly, this
has serious implications for the use of PLSDA to analyse CHD datasets.
PLSDA and other classification algorithms may have most success in biomarker discovery for
CHD in metabolomics in certain scenarios: (1). If the dataset under study represents a subtype of
the complex disease, so it is essentially homogeneous. (2). If, at the time of bio-specimen sampling,
etiological pathways had converged sufficiently, so the samples under analysis were exhibiting the
same pathway, so again, the dataset would essentially be homogeneous at that time point. However the
first scenario is unlikely to exist the phenotypic classification does not, in fact, represent a biologically
unique category but instead a lumping together of cases due to similar phenotypes, and the second
scenario is unlikely to exist if the sample timing captures the metabolomic activity at different stages
along the various etiological pathways of the disease or too early in the disease etiology at a point in
time where the pathways have not yet converged.
While multivariate modelling methods, such as PLSDA, often identify discriminating variables
that lead to good classification upon cross validation and permutation, these variables are unlikely
to be generalizable beyond the original system due to the complexity of the system from which they
are derived. The discriminating variables identified in this scenario are likely to be highly context
specific and might, in fact, not even be a revelation of real world phenomena but may, instead, merely
represent “a tautological relationship between a set of numbers” [72] derived from a static snapshot
analysis of a dynamic system.
An [63] eloquently defines what he calls The Denominator Problem in biomedical research as the
intrinsic inability of reductionist experimental biology to effectively reflect system denominator space,
where the denominator is defined as the population distribution of the total possible behaviour/state
space, as described by whatever metrics chosen, that biosystem. He explains how the requirements of
experimental biology serve to constrain the sampling of denominator space, which leads to extreme
sensitivity to conditions and irreproducibility. The author proposes that increased complexity and
sophistication in the form of multi-scale mathematical (MSM) and dynamic computational models,
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to account for the denominator subspace, will overcome this problem. Geman [38] also suggests
that global mathematical models over network scale configurations of genomic states and molecular
concentrations will overcome the failure of omics based predictors and signatures to translate to
clinical use.
Somewhat conversely, Karpievitch et al. describe how a major issue affecting the success of
biomarker discovery in metabolomics is that the long line from pre-processing to statistical inference in
data analysis is costly in terms of loss of degrees of freedom and accumulation of bias and errors [34].
At every step, there is a loss of degrees of freedom as we “use up” information in the dataset. Variability
introduced at each step is not communicated to the next step, which can lead to an over-fitting of the
data. Karpievitch et al. [34] suggest that the most natural solution to this problem is that processing and
inference are ideally carried out in the same step, as this will greatly increase the quality of results by
limiting the amount of bias communicated from one step to another. If this approach is not achievable,
then shortening the data analysis pipeline, where possible, will result in fewer decisions to be made
and, consequently, less opportunity for the introduction of bias, thereby increasing the possibility of
obtaining actual meaningful results.
Therefore, it may be the case that typical data analysis techniques employed in biomarker
discovery are at once too complex and not complex enough to tackle the biological heterogeneity
issue. Specifically, statistical learning techniques, such as PLSDA, may be inadequate to model the
heterogeneity and complexity of the “denominator subspace”, and, at the same time, they may be
overly complex, leading to loss of information from an already overtaxed source. The trade-off of
loss of degrees of freedom may not be balanced adequately by a gain in information. Until such a
time as the sophistication of the methods improves (i.e., until multi-scale-modelling can be achieved),
recognition of the limitations of what we can access from a static representation of a dynamic system
needs to be accepted. While not sophisticated, low constraint and low complexity analysis methods,
to search for biomarkers, may demonstrate improvements in generalisability. Figure 2 represents a
schematic of this proposed notion.
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dataset, f atures that ex ibit stable expression across all controls are a rich source of clinically applicable
inf rmation. In a CHD dataset, the case group has h dden substructure due to unknown hidden
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subgroups of disease, whereas in the controls, at least for the outcome of interest, that hidden
substructure does not exist. A feature that exhibits low variance or stable expression across a group
of healthy controls and perturbation, in at least some cases, is likely to be informative, and, more
importantly, that information is likely to be generalizable beyond the study at hand, since the feature
has shown stability across a group of patients (the controls) and, as such, has demonstrated that it is
impervious to context sensitivity (in the actual study at least). This would be a mechanism would
simultaneously leverage prior information into model building that would constrain model complexity
and overcome the issue of contextual sensitivity.
6. Discussion
“Formal Analysis freezes moments of a process into things” [73]. When Richard Levins wrote this
statement in his essay, “Formal analysis and the fluidity of science”, although he was not referring
specifically to metabolomics analysis, it is very apt. Metabolomics is considered the most complex omics
domains to model owing to its dynamic nature, which consists of non-linear relations (that are not fully
understood); its sensitivity to environmental fluxes; and its stochasticity. In metabolomics biomarker
discovery, analysis is carried out on a static, context specific representation of an extremely dynamic
system. Indeed, metabolomics is frequently described as a “snapshot” analysis. This snapshot then
undergoes a long line of processing to inference, using a complex model, with the aim of generalizability
to other static representations of complex domains.
The claim that multivariate approaches are more desirable than univariate selection processes for
biomarker discovery was assessed for microarray datasets, and univariate methods were found to
yield consistently better results than multivariate approaches [50]. A fair assessment of this claim has
not yet been made for metabolomics studies. While the understanding of the molecular architecture of
complex disease has undergone an awakening over the last decade in light of GWAS results, the de facto
multivariate data analysis methods for complex disease biomarker discovery (which established their
popularity with the original understanding of complex diseases as arising from common polygenic
variants) have remained largely unchanged. It can be assumed that the early optimism in the superiority
of supervised classification techniques in the search for biomarker signatures for complex diseases
was due to an under-appreciation of the complexity of the genome and, hence, of the heterogeneity of
complex diseases at the molecular level.
The path to biomarker discovery has been predicted to be tortuous [49]. In data analysis, a
variety of risk factors exist that contribute to the irreproducibility of results. Some of these risk factors
can be addressed, while others are more difficult to address (but can, at least, be acknowledged).
The risk factors inherent in metabolomics biomarker discovery can be compounded by employing
data driven approaches and applying imputation methods without considering the potential loss
of information. Heterogeneity of disease and datasets need to be accounted for via a more study
specific and disease specific approach as opposed to an indiscriminate, one size fits all, “big data”
approach [31]. That metabolomics ultimately holds the key to personalised medicine is not in question
in this perspective. However, a pragmatic approach to biomarker discovery is required, where the
clinical need, as well as the available biological knowledge and understanding of the molecular basis
of the disease under study (and its etiology), inform all aspects of the early discovery process, from
the design of experiment and the design of the biomarker discovery pipeline, to the choice of data
pretreatment and data analysis strategies.
The simplicity principle (also known as Occam’s Razor) tells us that more complex theories, due
to their complexity and flexibility, are more likely to fit more closely to the data, but simpler theories
will generalise better. The main aim of clinically applicable biomarker discovery is their subsequent
generalisability as opposed to their predictive performance in preliminary studies. In modelling,
any one of the three attributes (precision, realism, or generalisability) can be maximised at the
expense of the other two attributes [73]. For the purpose of biomarker discovery for clinical
application, the generalisability of the model, rather than its precision or realism, is the most
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important aspect. Alternatively, when an understanding of a biological system is sought, then the
importance of precision and realism supersedes generalisability. The discovery of biomarkers for
clinical diagnosis and prognosis is urgently required. In the intervening time until sophisticated
analyses, like multi scale methods, are implemented, simpler models may have more success in
identifying generalizable biomarkers.
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